National Institute for Health and Care Excellence

Published guidance, NICE advice and quality standards

Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatment TA1139 11 March 2026 11 March 2026 Durvalumab with gemcitabine and cisplatin for ...
National Institute for Health and Care Excellence

In development: Guidance, quality standards and advice

Tafasitamab with lenalidomide and R-CHOP for untreated high-intermediate-risk or high-risk diffuse large B-cell lymphoma [ID6568] Technology appraisal guidance 10 June 2027 Tafasitamab with ...
Wired

how-to

WIRED is obsessed with what comes next. Through rigorous investigations and game-changing reporting, we tell stories that don’t just reflect the moment—they help create it. When you look back in 10, ...